비교리스트

 카트 문의
시장보고서
상품코드
1371509

세계의 무균 주사제 수탁제조 아웃소싱(CMO) 시장(2024-2034년)

Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Report 2024-2034
발행일: | 리서치사: Visiongain | 페이지 정보: 영문 428 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 무균 주사제 CMO(수탁제조 아웃소싱) 시장 규모는 2034년까지 9.5%의 CAGR로 성장할 것으로 예측되고 있습니다.

제약업계의 연구 투자가 활발히 이루어지고 있으며, 첨단 기업은 매출의 평균 15%를 R&D에 투자하고 있습니다. 초기 단계 개발에 대한 R&D 투자가 증가하고 전임상 단계에 있는 잠재적 의약품의 양이 증가함에 따라 전임상 서비스도 생명과학 기업 사이에서 높은 수요를 보이고 있습니다. 많은 제약회사들이 신약과 치료제 개발을 지원하기 위해 R&D 비용을 늘리고 있으며, Roche, Pfizer, Merck, Bristol-Myers Squibb와 같은 대형 제약회사들은 2022년까지 연간 매출의 약 5분의 1을 R&D 비용으로 지출할 것으로 예상됩니다. 의약품 R&D 비용이 급증함에 따라 무균 주사제 CMO에 대한 수요도 확대되어 CMO에 많은 기회를 제공할 것으로 예상됩니다.

한편, 높은 운영 비용이 매출 증가를 가로막고 있습니다. 무균 의약품을 생산하기 위해서는 첨단 장비를 사용해야 합니다. 또한 FDA는 무균 주사제의 제조, 포장, 보관 및 유통에 더 많은 주의를 기울여야 하기 때문에 운영 비용이 높아 CMO 시장의 성장을 저해할 수 있습니다.

세계의 무균 주사제 CMO(수탁제조 아웃소싱) 시장을 조사했으며, 시장 개요, 시장 성장에 대한 각종 영향요인 분석, 시장 규모의 추이·예측, 각종 구분·지역/주요 국가별 내역, 경쟁 환경, 주요 기업의 개요 등을 정리하여 전해드립니다.

목차

제1장 리포트 개요

제2장 주요 요약

제3장 시장 개요

  • 주요 조사 결과
  • 시장 역학
    • 시장 촉진요인
    • 시장 억제요인
    • 시장 기회
  • COVID-19의 영향 분석
  • Porter's Five Forces 분석
  • SWOT 분석
  • PEST 분석

제4장 무균 주사제 CMO(수탁제조 아웃소싱) 시장 분석 : 분자 유형별

  • 주요 조사 결과
  • 시장 매력 지수
  • 시장 규모 추산·예측
  • 저분자
  • 고분자

제5장 무균 주사제 CMO(수탁제조 아웃소싱) 시장 분석 : 유형별

  • 주요 조사 결과
  • 시장 매력 지수
  • 시장 규모 추산·예측
  • 모노클로널 항체(mAb)
  • 사이토카인
  • 인슐린
  • 펩티드 호르몬
  • 백신
  • 면역글로불린
  • 혈액 인자
  • 펩티드 항생제
  • 기타

제6장 무균 주사제 CMO(수탁제조 아웃소싱) 시장 분석 : 용도별

  • 주요 조사 결과
  • 시장 매력 지수
  • 시장 규모 추산·예측
  • 암
  • 당뇨병
  • 심혈관질환
  • 중추신경계
  • 감염증
  • 기타

제7장 무균 주사제 CMO(수탁제조 아웃소싱) 시장 분석 : 용기 유형별

  • 주요 조사 결과
  • 시장 매력 지수
  • 시장 규모 추산·예측
  • 보틀
  • 앰플
  • 바이알
  • 프리필드 시린지
  • 백

제8장 무균 주사제 CMO(수탁제조 아웃소싱) 시장 분석 : 투여 경로별

  • 주요 조사 결과
  • 시장 매력 지수
  • 시장 규모 추산·예측
  • 피하
  • 정맥내
  • 근육내
  • 기타

제9장 무균 주사제 CMO(수탁제조 아웃소싱) 시장 분석 : 서비스별

  • 주요 조사 결과
  • 시장 매력 지수
  • 시장 규모 추산·예측
  • 생체 분석 검사
  • 메소드 개발·검증
  • 안정성 시험
  • 기타

제10장 무균 주사제 CMO(수탁제조 아웃소싱) 시장 분석 : 지역별

  • 주요 조사 결과
  • 시장 규모 추산·예측

제11장 북미의 무균 주사제 CMO(수탁제조 아웃소싱) 시장 분석

제12장 유럽의 무균 주사제 CMO(수탁제조 아웃소싱) 시장 분석

제13장 아시아태평양의 무균 주사제 CMO(수탁제조 아웃소싱) 시장 분석

제14장 라틴아메리카의 무균 주사제 CMO(수탁제조 아웃소싱) 시장 분석

제15장 중동 및 아프리카의 무균 주사제 CMO(수탁제조 아웃소싱) 시장 분석

제16장 기업 개요

  • 경쟁 구도
  • Aenova Group
  • Almac Group
  • WuXi AppTec
  • Boehringer Ingelheim International GmbH
  • Catalent, Inc.
  • CordenPharma International
  • Evonik Industries AG
  • FAMAR Health Care Services
  • Fresenius Kabi AG
  • Grifols, S.A.
  • Hikma Pharmaceuticals PLC
  • Jubilant Pharmova Limited
  • Lonza
  • Patheon Pharma Services(Thermo Fisher Scientific Inc.)
  • Pfizer Inc.
  • Recipharm AB
  • Siegfried Holding AG
  • Nexus Pharmaceuticals, LLC
  • Avara Pharmaceutical Services, Inc.
  • Lilly
  • Adare Pharma Solutions
  • Vetter Pharma
  • Piramal Pharma Solutions

제17장 결론·제안

  • Visiongain으로부터의 결론
  • 시장 참여 기업에 대한 제안
KSA 23.11.13

The global Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs market is projected to grow at a CAGR of 9.5% by 2034.

“The Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Report 2024-2034”: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Increasing Investments in Pharmaceutical R&D and Increasing Demand for Biological are Driving the Market Growth

Research is substantially funded in the pharmaceutical industry, with forward-thinking businesses allocating 15% of their sales on average to R&D. Due to a growth in R&D investment on early-stage development and the volume of potential drugs at the preclinical stage, preclinical services are also in high demand among life science firms.Many pharmaceutical companies have increased their R&D spending to help with the development of new medicines and therapies. In 2022, the largest pharmaceutical firms, including Roche, Pfizer, Merck, and Bristol-Myers Squibb, would devote about one-fifth of their annual revenue to R&D efforts. As a result of the surge in pharmaceutical R&D spending, it is projected that the need for Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs will expand, providing CMOs with more opportunities to provide outsourcing services.

As a result, many people have investigated cost-cutting options, like outsourcing manufacturing. As more patents are slated to expire, more efforts are being made to uncover biologics and novel chemicals, and the expense of R&D is rising, drug makers and sponsors are under greater pressure to make up for the financial losses brought on by generics. This is making drug research even more expensive and complex. Even government organisations are turning to CROs to outsource their clinical production in order to have access to the necessary tools and expertise, as well as to cut costs and outsourcing timelines.

High Operational Costs Likely to Challenge Industry Growth

The high operational costs are impeding the rise of global revenue. Use of advanced equipment is necessary while producing sterile medications. For instance, a biotechnology business may need to create 3,000 vials of an injectable medicine (sterile fill and finish) in order to carry out a phase I-II clinical study in oncology. The projected costs to manufacture pharmaceutical items are as follows: project planning & management: $35,000; supplier management: $4,000; and drug product analytical development: $40,000. It is believed that the biotechnology company will assign the production task to a different contract drug manufacturing organization (CDMO). Furthermore, due to FDA requirements mandating extreme attention be taken in the manufacturing, packaging, storage, and distribution of sterile injectable pharmaceuticals, the operational cost burden is significant, which can hamper the CMO market growth.

What Questions Should You Ask Before Buying a Market Research Report?

  • How is the Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs market evolving?
  • What is driving and restraining the Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs market?
  • How will each point of care diagnostic submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?
  • How will the market shares for each Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs submarket develop from 2024 to 2034?
  • What will be the main driver for the overall market from 2024 to 2034?
  • Will leading Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?
  • Who are the leading players and what are their prospects over the forecast period?
  • What are the Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs projects for these leading companies?
  • How will the industry evolve during the period between 2024 and 2034? What are the implications of Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs projects taking place now and over the next 10 years?
  • Is there a greater need for product commercialisation to further scale the Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs market?
  • Where is the Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs market heading and how can you ensure you are at the forefront of the market?
  • What are the best investment options for new product and service lines?
  • What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs market today, and over the next 10 years:

  • Our 428-page report provides 170 tables, 254 charts, and graphs exclusively to you
  • The report highlights key lucrative areas in the industry so you can target them - NOW
  • It contains in-depth analysis of global, regional and national sales and growth
  • It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2034 and other analyses reveal commercial prospects

  • In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares
  • You will find original analyses, with business outlooks and developments
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, ""V" ", "L", "W" and "U" are discussed in this report.

Segments Covered in the Report:

Molecule Type

  • Small Molecules
  • Large Molecules

Type

  • Monoclonal Antibodies
  • Cytokines
  • Insulin
  • Peptide Hormones
  • Vaccines
  • Immunoglobulins
  • Blood Factors
  • Peptide Antibiotics
  • Other Types

Application

  • Cancer
  • Diabetes
  • Cardiovascular diseases
  • CNS
  • Infectious
  • Others

Container Type

  • Bottles
  • Ampoules
  • Vials
  • Prefilled syringes
  • Bags

Route of Administration

  • Subcutaneous
  • Intravenous
  • Intramuscular
  • Other Route of Administration

Service

  • Bioanalytical Testing
  • Method Development & Validation
  • Stability Testing
  • Others

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 18 leading national markets:

North America

  • U.S
  • Canada

Europe

  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Switzerland
  • Netherlands
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America

MEA

  • GCC
  • South Africa
  • Egypt
  • Rest of MEA

The report also includes profiles and for some of the leading companies in the Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market, 2024 to 2034, with a focus on this segment of these companies' operations.

Leading companies and the potential for market growth:

  • Adare Pharma Solutions
  • Aenova Group
  • Almac Group
  • Avara Pharmaceutical Services, Inc
  • Boehringer Ingelheim International GmbH
  • Catalent, Inc
  • CordenPharma International
  • Evonik Industries AG
  • F. Hoffmann-La Roche Ltd
  • FAMAR Health Care Services
  • Fresenius Kabi AG
  • Grifols, S.A
  • Hikma Pharmaceuticals PLC
  • Jubilant Pharmova Limited
  • Lilly
  • Lonza
  • Nexus Pharmaceuticals, LLC
  • Patheon Pharma Services (Thermo Fisher Scientific Inc.)
  • Pfizer Inc
  • Piramal Pharma Solutions
  • Recipharm AB
  • Siegfried Holding AG
  • Vetter Pharma
  • Wuxi AppTec

Overall world revenue for Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market, 2024 to 2034 in terms of value the market will surpass US$24.2 billion in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market, 2024 to 2034 report help you?

In summary, our 420+ page report provides you with the following knowledge:

  • Revenue forecasts to 2034 for Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs market, with forecasts for type, molecule type, application, container type, route of administration, services, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
  • Revenue forecasts to 2034 for five regional and 21 key national markets - See forecasts for the Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, Spain, Switzerland, Netherlands, China, India, Japan, Australia, South Korea, South East Asia, Argentina, GCC, South Africa, and Egypt among other prominent economies.
  • Prospects for established firms and those seeking to enter the market - including company profiles for 25 of the major companies involved in the Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market, 2024 to 2034.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to CMO of Sterile Injectable Drugs Market
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report for?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Market Dynamics
    • 3.2.1 Market Driving Factors
      • 3.2.1.1 Growing Focus on Development to Treat Cancer
      • 3.2.1.2 Rising Prevalence of Chronic Diseases
      • 3.2.1.3 Rapid FDA Approvals of Sterile Injectable Drugs to Fuel Market Growth
      • 3.2.1.4 As Manufacturers Invest in New Manufacturing Facilities, The Demand for Sterile Injectable is expected to Rise
      • 3.2.1.5 Increasing Demand for Biological is Expected to Drive the Demand
      • 3.2.1.6 Increasing Investments in Pharmaceutical R&D
    • 3.2.2 Market Restraining Factors
      • 3.2.2.1 Growing Competition from Small Manufacturers
      • 3.2.2.2 High Operational Costs
      • 3.2.2.3 Inadequate Healthcare Infrastructure Across Developing Economies Challenging Market Growth
    • 3.2.3 Market Opportunities
      • 3.2.3.1 Prefilled Syringes to Offer Lucrative Growth Prospects
      • 3.2.3.2 Growing Investments
      • 3.2.3.3 Expanding Clinical Trial Opportunities in the Asia Pacific Region
  • 3.3 COVID-19 Impact Analysis
  • 3.4 Porter's Five Forces Analysis
    • 3.4.1 Competitive Rivalry
    • 3.4.2 Threat of New Entrants
    • 3.4.3 Threat of Substitutes
    • 3.4.4 Bargaining Power of Buyers
    • 3.4.5 Bargaining Power of Suppliers
  • 3.5 SWOT Analysis
  • 3.6 PEST Analysis
    • 3.6.1 Political Factors Impacting CMO of Sterile Injectable Drugs Market
    • 3.6.2 Economic Factors Impacting CMO of Sterile Injectable Drugs Market
    • 3.6.3 Social Factors Impacting CMO of Sterile Injectable Drugs Market
    • 3.6.4 Technological Factors Impacting CMO of Sterile Injectable Drugs Market

4 CMO of Sterile Injectable Drugs Market Analysis by Molecule Type

  • 4.1 Key Findings
  • 4.2 Molecule Type Segment: Market Attractiveness Index
  • 4.3 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Molecule Type
  • 4.4 Small Molecule
    • 4.4.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 4.4.2 Market Share by Region, 2024 & 2034 (%)
  • 4.5 Large Molecule
    • 4.5.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 4.5.2 Market Share by Region, 2024 & 2034 (%)

5 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market, by Type, 2024-2034

  • 5.1 Key Findings
  • 5.2 Type Segment: Market Attractiveness Index
  • 5.3 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market, by Type
  • 5.4 Monoclonal Antibodies (mAbs)
    • 5.4.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.4.2 Market Share by Region, 2024 & 2034 (%)
  • 5.5 Cytokines
    • 5.5.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.5.2 Market Share by Region, 2024 & 2034 (%)
  • 5.6 Insulin
    • 5.6.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.6.2 Market Share by Region, 2024 & 2034 (%)
  • 5.7 Peptide Hormones
    • 5.7.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.7.2 Market Share by Region, 2024 & 2034 (%)
  • 5.8 Vaccines
    • 5.8.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.8.2 Market Share by Region, 2024 & 2034 (%)
  • 5.9 Immunoglobulins
    • 5.9.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.9.2 Market Share by Region, 2024 & 2034 (%)
  • 5.10 Blood Factor
    • 5.10.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.10.2 Market Share by Region, 2024 & 2034 (%)
  • 5.11 Peptide Antibiotics
    • 5.11.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.11.2 Market Share by Region, 2024 & 2034 (%)
  • 5.12 Other Type
    • 5.12.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 5.12.2 Market Share by Region, 2024 & 2034 (%)

6 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Application

  • 6.1 Key Findings
  • 6.2 Application Segment: Market Attractiveness Index
  • 6.3 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Application
  • 6.4 Cancer
    • 6.4.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 6.4.2 Market Share by Region, 2024 & 2034 (%)
  • 6.5 Diabetes
    • 6.5.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 6.5.2 Market Share by Region, 2024 & 2034 (%)
  • 6.6 Cardiovascular Diseases
    • 6.6.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 6.6.2 Market Share by Region, 2024 & 2034 (%)
  • 6.7 CNS
    • 6.7.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 6.7.2 Market Share by Region, 2024 & 2034 (%)
  • 6.8 Infectious
    • 6.8.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 6.8.2 Market Share by Region, 2024 & 2034 (%)
  • 6.9 Others
    • 6.9.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 6.9.2 Market Share by Region, 2024 & 2034 (%)

7 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Container Type

  • 7.1 Key Findings
  • 7.2 Container Type Segment: Market Attractiveness Index
  • 7.3 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Container Type
  • 7.4 Bottles
    • 7.4.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 7.4.2 Market Share by Region, 2024 & 2034 (%)
  • 7.5 Ampoules
    • 7.5.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 7.5.2 Market Share by Region, 2024 & 2034 (%)
  • 7.6 Vials
    • 7.6.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 7.6.2 Market Share by Region, 2024 & 2034 (%)
  • 7.7 Prefilled Syringes
    • 7.7.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 7.7.2 Market Share by Region, 2024 & 2034 (%)
  • 7.8 Bags
    • 7.8.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 7.8.2 Market Share by Region, 2024 & 2034 (%)

8 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Route of Administration

  • 8.1 Key Findings
  • 8.2 Route of Administration Segment: Market Attractiveness Index
  • 8.3 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Route of Administration
  • 8.4 Subcutaneous
    • 8.4.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 8.4.2 Market Share by Region, 2024 & 2034 (%)
  • 8.5 Intravenous
    • 8.5.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 8.5.2 Market Share by Region, 2024 & 2034 (%)
  • 8.6 Intramuscular
    • 8.6.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 8.6.2 Market Share by Region, 2024 & 2034 (%)
  • 8.7 Other Route of Administration
    • 8.7.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 8.7.2 Market Share by Region, 2024 & 2034 (%)

9 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Service

  • 9.1 Key Findings
  • 9.2 Service Segment: Market Attractiveness Index
  • 9.3 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Service
  • 9.4 Bioanalytical Testing
    • 9.4.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 9.4.2 Market Share by Region, 2024 & 2034 (%)
  • 9.5 Method Development & Validation
    • 9.5.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 9.5.2 Market Share by Region, 2024 & 2034 (%)
  • 9.6 Stability Testing
    • 9.6.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 9.6.2 Market Share by Region, 2024 & 2034 (%)
  • 9.7 Others
    • 9.7.1 Market Size by Region, 2024-2034 (US$ Billion)
    • 9.7.2 Market Share by Region, 2024 & 2034 (%)

10 Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis by Region

  • 10.1 Key Findings
  • 10.2 Regional Market Size Estimation and Forecast

11 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis

  • 11.1 Key Findings
  • 11.2 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Attractiveness Index
  • 11.3 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 11.4 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Country
  • 11.5 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Molecule Type
  • 11.6 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Type
  • 11.7 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Application
  • 11.8 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Container Type
  • 11.9 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Route of Administration
  • 11.10 North America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Service
  • 11.11 U.S. Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
  • 11.12 Canada Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis

12 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis

  • 12.1 Key Findings
  • 12.2 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Attractiveness Index
  • 12.3 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 12.4 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Country
  • 12.5 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Molecule Type
  • 12.6 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Type
  • 12.7 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Application
  • 12.8 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Container Type
  • 12.9 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Route of Administration
  • 12.10 Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Service
  • 12.11 Germany Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
  • 12.12 UK Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
  • 12.13 France Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
  • 12.14 Italy Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
  • 12.15 Spain Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
  • 12.16 Switzerland Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
  • 12.17 Netherlands Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
  • 12.18 Rest of Europe Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis

13 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis

  • 13.1 Key Findings
  • 13.2 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Attractiveness Index
  • 13.3 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 13.4 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Country
  • 13.5 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Molecule Type
  • 13.6 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Type
  • 13.7 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Application
  • 13.8 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Container Type
  • 13.9 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Route of Administration
  • 13.10 Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Service
  • 13.11 Japan Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
  • 13.12 China Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
  • 13.13 India Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
  • 13.14 Australia Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
  • 13.15 South Korea Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
  • 13.16 South East Asia Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
  • 13.17 Rest of Asia Pacific Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis

14 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis

  • 14.1 Key Findings
  • 14.2 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Attractiveness Index
  • 14.3 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 14.4 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Country
  • 14.5 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Molecule Type
  • 14.6 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Type
  • 14.7 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Application
  • 14.8 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Container Type
  • 14.9 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Route of Administration
  • 14.10 Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Service
  • 14.11 Brazil Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
  • 14.12 Mexico Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
  • 14.13 Argentina Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
  • 14.14 Rest of Latin America Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis

15 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis

  • 15.1 Key Findings
  • 15.2 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Attractiveness Index
  • 15.3 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market by Country, 2024, 2029 & 2034 (US$ Billion)
  • 15.4 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Country
  • 15.5 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Molecule Type
  • 15.6 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Type
  • 15.7 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Application
  • 15.8 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Container Type
  • 15.9 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Route of Administration
  • 15.10 MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Size Estimation and Forecast by Service
  • 15.11 GCC Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
  • 15.12 South Africa Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
  • 15.13 Egypt Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis
  • 15.14 Rest of MEA Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Analysis

16 Company Profiles

  • 16.1 Competitive Landscape, 2022
  • 16.2 Aenova Group
    • 16.2.1 Company Snapshot
    • 16.2.2 Company Overview
    • 16.2.3 Financial Analysis
      • 16.2.3.1 Net Revenue, 2018-2022
      • 16.2.3.2 Segment Market Shares, 2022
      • 16.2.3.3 Regional Market Shares, 2022
    • 16.2.4 Service Benchmarking
    • 16.2.5 Strategic Outlook
  • 16.3 Almac Group
    • 16.3.1 Company Snapshot
    • 16.3.2 Company Overview
    • 16.3.3 Service Benchmarking
    • 16.3.4 Strategic Outlook
  • 16.4 WuXi AppTec
    • 16.4.1 Company Snapshot
    • 16.4.2 Company Overview
    • 16.4.3 Financial Analysis
      • 16.4.3.1 Net Revenue, 2018-2022
      • 16.4.3.2 R&D, 2018-2022
      • 16.4.3.3 Segment Market Shares, 2022
      • 16.4.3.4 Regional Market Shares, 2022
    • 16.4.4 Service Benchmarking
    • 16.4.5 Strategic Outlook
  • 16.5 Boehringer Ingelheim International GmbH
    • 16.5.1 Company Snapshot
    • 16.5.2 Company Overview
    • 16.5.3 Financial Analysis
      • 16.5.3.1 Net Revenue, 2018-2022
      • 16.5.3.2 Segment Market Shares, 2022
      • 16.5.3.3 Regional Market Shares, 2022
    • 16.5.4 Service Benchmarking
    • 16.5.5 Strategic Outlook
  • 16.6 Catalent, Inc.
    • 16.6.1 Company Snapshot
    • 16.6.2 Company Overview
    • 16.6.3 Financial Analysis
      • 16.6.3.1 Net Revenue, 2018-2022
      • 16.6.3.2 Segment Market Shares, 2022
      • 16.6.3.3 Regional Market Shares, 2022
    • 16.6.4 Service Benchmarking
    • 16.6.5 Strategic Outlook
  • 16.7 CordenPharma International
    • 16.7.1 Company Snapshot
    • 16.7.2 Company Overview
    • 16.7.3 Service Benchmarking
    • 16.7.4 Strategic Outlook
  • 16.8 Evonik Industries AG
    • 16.8.1 Company Snapshot
    • 16.8.2 Company Overview
    • 16.8.3 Financial Analysis
      • 16.8.3.1 Net Revenue, 2018-2022
      • 16.8.3.2 R&D, 2018-2022
      • 16.8.3.3 Segment Market Shares, 2022
      • 16.8.3.4 Regional Market Shares, 2022
    • 16.8.4 Service Benchmarking
    • 16.8.5 Strategic Outlook
  • 16.9 FAMAR Health Care Services
    • 16.9.1 Company Snapshot
    • 16.9.2 Company Overview
    • 16.9.3 Service Benchmarking
    • 16.9.4 Strategic Outlook
  • 16.10 Fresenius Kabi AG
    • 16.10.1 Company Snapshot
    • 16.10.2 Company Overview
    • 16.10.3 Financial Analysis
      • 16.10.3.1 Net Revenue, 2018-2022
      • 16.10.3.2 R&D, 2018-2022
      • 16.10.3.3 Segment Market Shares, 2022
      • 16.10.3.4 Regional Market Shares, 2022
    • 16.10.4 Service Benchmarking
    • 16.10.5 Strategic Outlook
  • 16.11 Grifols, S.A.
    • 16.11.1 Company Snapshot
    • 16.11.2 Company Overview
    • 16.11.3 Financial Analysis
      • 16.11.3.1 Net Revenue, 2018-2022
      • 16.11.3.2 R&D, 2018-2022
      • 16.11.3.3 Segment Market Shares, 2022
      • 16.11.3.4 Regional Market Shares, 2022
    • 16.11.4 Service Benchmarking
    • 16.11.5 Strategic Outlook
  • 16.12 Hikma Pharmaceuticals PLC
    • 16.12.1 Company Snapshot
    • 16.12.2 Company Overview
    • 16.12.3 Financial Analysis
      • 16.12.3.1 Net Revenue, 2018-2022
      • 16.12.3.2 R&D, 2018-2022
      • 16.12.3.3 Segment Market Shares, 2022
      • 16.12.3.4 Regional Market Shares, 2022
    • 16.12.4 Service Benchmarking
    • 16.12.5 Strategic Outlook
  • 16.13 Jubilant Pharmova Limited
    • 16.13.1 Company Snapshot
    • 16.13.2 Company Overview
    • 16.13.3 Financial Analysis
      • 16.13.3.1 Net Revenue, 2018-2022
      • 16.13.3.2 Segment Market Shares, 2022
      • 16.13.3.3 Regional Market Shares, 2022
    • 16.13.4 Service Benchmarking
    • 16.13.5 Strategic Outlook
  • 16.14 Lonza
    • 16.14.1 Company Snapshot
    • 16.14.2 Company Overview
    • 16.14.3 Financial Analysis
      • 16.14.3.1 Net Revenue, 2018-2022
      • 16.14.3.2 R&D, 2018-2022
      • 16.14.3.3 Segment Market Shares, 2022
      • 16.14.3.4 Regional Market Shares, 2022
    • 16.14.4 Service Benchmarking
    • 16.14.5 Strategic Outlook
  • 16.15 Patheon Pharma Services (Thermo Fisher Scientific Inc.)
    • 16.15.1 Company Snapshot
    • 16.15.2 Company Overview
    • 16.15.3 Financial Analysis
      • 16.15.3.1 Net Revenue, 2018-2022
      • 16.15.3.2 R&D, 2018-2022
      • 16.15.3.3 Segment Market Shares, 2022
      • 16.15.3.4 Regional Market Shares, 2022
    • 16.15.4 Service Benchmarking
    • 16.15.5 Strategic Outlook
  • 16.16 Pfizer Inc.
    • 16.16.1 Company Snapshot
    • 16.16.2 Company Overview
    • 16.16.3 Financial Analysis
      • 16.16.3.1 Net Revenue, 2018-2022
      • 16.16.3.2 R&D, 2018-2022
      • 16.16.3.3 Segment Market Shares, 2022
      • 16.16.3.4 Regional Market Shares, 2022
    • 16.16.4 Service Benchmarking
    • 16.16.5 Strategic Outlook
  • 16.17 Recipharm AB
    • 16.17.1 Company Snapshot
    • 16.17.2 Company Overview
    • 16.17.3 Financial Analysis
      • 16.17.3.1 Net Revenue, 2018-2022
    • 16.17.4 Service Benchmarking
    • 16.17.5 Strategic Outlook
  • 16.18 Siegfried Holding AG
    • 16.18.1 Company Snapshot
    • 16.18.2 Company Overview
    • 16.18.3 Financial Analysis
      • 16.18.3.1 Net Revenue, 2018-2022
      • 16.18.3.2 R&D, 2018-2022
      • 16.18.3.3 Segment Market Shares, 2022
    • 16.18.4 Service Benchmarking
    • 16.18.5 Strategic Outlook
  • 16.19 Nexus Pharmaceuticals, LLC
    • 16.19.1 Company Snapshot
    • 16.19.2 Company Overview
    • 16.19.3 Service Benchmarking
    • 16.19.4 Strategic Outlook
  • 16.20 Avara Pharmaceutical Services, Inc.
    • 16.20.1 Company Snapshot
    • 16.20.2 Company Overview
    • 16.20.3 Service Benchmarking
  • 16.21 Lilly
    • 16.21.1 Company Snapshot
    • 16.21.2 Company Overview
    • 16.21.3 Financial Analysis
      • 16.21.3.1 Net Revenue, 2018-2022
      • 16.21.3.2 R&D, 2018-2022
      • 16.21.3.3 Regional Market Shares, 2022
    • 16.21.4 Service Benchmarking
    • 16.21.5 Strategic Outlook
  • 16.22 Adare Pharma Solutions
    • 16.22.1 Company Snapshot
    • 16.22.2 Company Overview
    • 16.22.3 Service Benchmarking
    • 16.22.4 Strategic Outlook
  • 16.23 Vetter Pharma
    • 16.23.1 Company Snapshot
    • 16.23.2 Company Overview
    • 16.23.3 Service Benchmarking
    • 16.23.4 Strategic Outlook
  • 16.24 Piramal Pharma Solutions
    • 16.24.1 Company Snapshot
    • 16.24.2 Company Overview
    • 16.24.3 Service Benchmarking
    • 16.24.4 Strategic Outlook

17 Conclusion and Recommendations

  • 17.1 Concluding Remarks from Visiongain
  • 17.2 Recommendations for Market Players
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제